Yali Friedman, Ph.D. retweetledi
The Code Breaker: Jennifer Doudna, gene editing, and the future of the human race commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D.
7K posts
Yali Friedman, Ph.D.
@jcommbiotech
Journal of Commercial Biotechnology is a quarterly peer-reviewed journal focused on the business of biotechnology. Free sample papers at http://t.co/Jf2NAojbvd
Washington, DC Katılım Mart 2011
143 Takip Edilen3.5K Takipçiler
Yali Friedman, Ph.D. retweetledi
Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
A Note on Corporate Open Innovation: Engagement with Startups commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Putting Theory into Practice at BridgeBio commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Illumina Accelerator: Next-Gen Corporate Accelerator with a Customer-Creation Focus commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
A Case Study - NeuBase Therapeutics, Inc. commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Building technology enabled platform companies in Biopharma – a perspective on early-stage value creation from Millennium, Alnylam, Moderna, & Kymera commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Foundational Tools for Building a New Bioeconomy commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Abridge: A mission driven approach to machine learning for healthcare conversation commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Value over Volume: Maximizing Resources by Prioritizing Value: The Dubai Healthcare Experience commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Using Lean Startup to Discover Customers in the mHealth Industry: Current Landscape and Challenges commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Bioentrepreneurship education: where have we been and where to next? commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Vaccine Hesitancy: When Political Miscommunication Replaces Scientific Benefit/Risk Assessment commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
A System Review of Bioentrepreneurship Education commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Platform technology management of biotechnology companies in Japan commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
CONSENSUS ON METRICS FOR THE ASSESSMENT OF A MEDICAL SCIENCE LIAISON USING THE DELPHI METHOD commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
A conversation on accelerating innovation in biopharma and life sciences through global collaboration and alliances commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
A Note From the Editor in Chief commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
Considerations for Potential Global Expansion of Serum Institute of India commercialbiotechnology.com/index.php/jcb/…
English
Yali Friedman, Ph.D. retweetledi
The Role of the Biotechnology Industry in Addressing Health Inequities in Africa: Strengthening the Entire Health Care Value Chain commercialbiotechnology.com/index.php/jcb/…
English